Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Limited / TESARO, Inc.

2017 · Licensing/Option · $340M · Complete

Announcement Sentiment

Strongly positive

TESARO licensed Japan rights for niraparib in all tumor types and South Korea/Taiwan/Russia/Australia rights in all tumors except prostate cancer to Takeda. TESARO received $100M upfront plus up to $240M in regulatory and commercial milestones, plus tiered double-digit royalties on Takeda territory net sales. Niraparib is the PARP inhibitor approved as ZEJULA in ovarian cancer maintenance.

Key facts

Announced Jul 27, 2017
Closed Jul 27, 2017
Deal value $340M
Deal type Licensing/Option
Therapeutic area Ovarian cancer and other solid tumors
Indications Ovarian cancer and other solid tumors
Key assets Niraparib (ZEJULA)
Mechanism PARP (poly ADP-ribose polymerase) inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals